EQT vs. MXC, EOG, NOG, HNR, SUN, WRES, VAL, WEB, CRC, and NBL
Should you be buying EQTEC stock or one of its competitors? The main competitors of EQTEC include Argent BioPharma (MXC), Europa Oil & Gas (EOG), Nostrum Oil & Gas (NOG), Highlands Natural Resources (HNR), Surgical Innovations Group (SUN), W Resources (WRES), ValiRx (VAL), Webis (WEB), Circle Property (CRC), and 18564 (NBL.L) (NBL). These companies are all part of the "petroleum and natural gas" industry.
EQTEC (LON:EQT) and Argent BioPharma (LON:MXC) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Argent BioPharma's return on equity of 0.00% beat EQTEC's return on equity.
2.5% of EQTEC shares are owned by institutional investors. Comparatively, 1.2% of Argent BioPharma shares are owned by institutional investors. 26.3% of EQTEC shares are owned by insiders. Comparatively, 8.2% of Argent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, EQTEC had 1 more articles in the media than Argent BioPharma. MarketBeat recorded 1 mentions for EQTEC and 0 mentions for Argent BioPharma. EQTEC's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.
EQTEC has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Argent BioPharma has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
EQTEC received 71 more outperform votes than Argent BioPharma when rated by MarketBeat users.
Argent BioPharma has lower revenue, but higher earnings than EQTEC. Argent BioPharma is trading at a lower price-to-earnings ratio than EQTEC, indicating that it is currently the more affordable of the two stocks.
Summary
EQTEC beats Argent BioPharma on 9 of the 12 factors compared between the two stocks.
Get EQTEC News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free EQT Stock Alerts